CASE STUDY

L9 - RxIdentic "BioBetter"™ Developed

Nortadalafil

The Cost for PharmaCo’s to develop a new drug is over
$1 Billion

More effective and less toxic than the originator drug

Reduced molecular weight from 375.4 g/mol to 45.4 g/mol: a 9-fold reduction

Reduced clinical dosage from 50 mg to 30 mg

Improved bioaccumulation: L9-Nortadalafil dosage “once or twice weekly” instead of ‘every other day’

This business model can be replicated over and over again with many other non-biological drugs, where drugs that have expired patents may have the opportunity to be re-patented.